VolitionRX Reports Positive Results from Trial

VolitionRX, a clinical-stage life sciences company, reported study results that it said continue to show that the Nu.Q Colorectal Cancer Screening Triage Test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.

The company said that the Nu.Q Triage test was able to prevent 24.5% of colonoscopies and detect almost 95% of colorectal cancers and 87.9% of high-risk adenomas. “It further strengthens the case for the Nu.Q Colorectal Cancer Screening Triage test to be incorporated into colorectal cancer screening programs,” said Louise Day, chief marketing and communications officer at VolitionRX.

Leave A Reply

Your email address will not be published.